 SAN DIEGO, July 16, 2021 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET. 